The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N06 | Psychoanaleptics | |
| 3 | N06B | Psychostimulants, agents used for ADHD and nootropics | |
| 4 | N06BA | Centrally acting sympathomimetics | |
| 5 | N06BA14 |
| Active Ingredient | Description | |
|---|---|---|
| Solriamfetol |
Solriamfetol is indicated to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Its mechanism of action has not been fully characterised. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine (noradrenaline) reuptake inhibitor (DNRI). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| SUNOSI Film‑coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
